- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04294940
Impact of a Digital Solution (CardiCare™) on Cardiorespiratory Fitness Improvement in Patients Discharged From a Phase 2 Cardiac Rehabilitation Following an Acute Coronary Syndrome
Coronary heart disease is a partial inability of the coronary arteries to supply the heart muscle due to their narrowing. There is angina and myocardial infarction. Coronary heart disease is the first cause of non-communicated deaths and years of life lost.
After hospital discharge, a few days following the acute care of a coronary heart disease, a formal Cardiac Rehabilitation programme (CR) is usually provided. CR is a comprehensive programme involving exercise training, risk factor modification, education and psychological support. It is generally sequenced in 4 phases. Phase 1 begins at the hospital and consists of early mobilisation and education. Most phase 2 CR models are based upon supervised ambulatory outpatient programmes. Maintenance (phase 3 and 4) follows the ambulatory programme in which physical fitness and risk factor control are supported in a minimally supervised setting.
Despite high-grade recommendations and abundant clinical evidence, a CR program is not always implemented and the patients are not systematically referred after discharge from a phase 1 CR. Furthermore, compliance to pharmacological treatments and changes in lifestyle and diet are hugely neglected following a phase 2 CR and an important number of patients resume a sedentary lifestyle.
A growing body of evidence supports the use of digital tools such as smartphones and tablets in helping the patients achieve their goals in terms of physical exercise, risk-factor reduction and diet improvement.
Ad Scientiam has developed CardiCare™, a mobile application intended to provide a personalised physical training plan contributing to stabilise or improve cardiorespiratory fitness through improvement of VO2max.
The mobile application CardiCare™ is to be used by patients after an acute coronary syndrome, graduated from a phase 2 cardiac rehabilitation program in a cardiac rehabilitation centre and entering in phase 3 CR.
The mobile application CardiCare™ consists of several modules:
- A physical activity recommendation engine, providing personalised weekly activity schedule, self-adapting to the patient's clinical characteristics, physical capacity and sport preferences through a proprietary algorithm
- Self-administered questionnaires to assess perceived exertion, chest pain, weight variations, patient's quality of life
- Passive monitoring of the patient's physical activity through Apple's HealthKit and Google's Fit
- Informational content about cardiovascular diseases, risk factor reduction and chest pain action plan The investigator's work hypothesis is that, compared to standard care, CardiCare™ will stabilise or improve the cardiorespiratory fitness (VO2max) acquired post-CR.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Issy les Moulineaux, France
- Corentin Celton hospital
-
Paris, France
- Lariboisière Hospital
-
Rennes, France
- Saint-Yves clinic
-
Villeneuve-Saint-Denis, France
- Brie Cardiac Readaptation Centre
-
-
-
-
-
Pavia, Italy
- Maugeri Scientific Clinical Institutes
-
Roma, Italy
- Scientific Institute of Hospitalization and Care San Raffaele Pisana
-
-
-
-
-
Carnaxide, Portugal
- CHOL - Santa Cruz hospital
-
Lisboa, Portugal
- CHULN - Santa Marta hospital
-
-
-
-
-
Madrid, Spain
- Carlos III - La Paz Hospital
-
Santiago De Compostela, Spain
- Santiago University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects ≥ 18 years old.
- Diagnosis of an Acute Coronary Syndrome in the last 3 months, documented by angiographically-proven coronary artery disease or hospitalisation report.
- Graduated from a phase 2 cardiac rehabilitation, ready to enter a phase 3 CR at home.
- Having agreed to perform a cardiopulmonary exercise testing and blood count at the inclusion or having performed a cardiopulmonary exercise testing and blood count within the last week.
- Owning a personal smartphone (Android 5.0 or beyond / iPhone 5s and newer supporting IOS 12 and beyond) with Wifi or a data plan (3G/4G).
- Able to use a smartphone (e.g. no vision, hearing, cognitive or dexterity impairment).
- Having agreed to install CardiCare™ application on their own smartphone.
- Having agreed to wear an actigraph at all times and install the actigraph application (CenterPoint Sync) on their smartphone.
- Enrolled in or benefiting of a national health system.
- Having read the information sheet and signed the informed consent form.
Non-inclusion Criteria:
- Treated with Coronary Artery Bypass Grafting.
- Cardiac surgery in the last 12 weeks.
- Planned revascularisation or surgery in the next 6 months.
- Clinical heart failure or Left Ventricular Ejection Fraction < 40% documented within the last 2 months.
- Severe valvular disease.
- Severe pulmonary disease.
- Chronic kidney disease (stages III-V).
- Drug or/and alcohol abuse (as per clinician's judgment).
- Unstable angina.
- Osteoarticular condition or other reasons that limit exercise for more than 4 months (clinician's judgment).
- Uncontrolled hypertension (resting Diastolic BP>100 mmHg and resting Systolic BP >200 mmHg).
- Severe/uncontrolled arrhythmia.
- Systemic medical diseases that are likely to affect cognitive functioning.
- Pregnant women confirmed by a pregnancy test at the inclusion.
- Participation to another interventional clinical trial (category 1).
- Illiterate or not proficient in the language of the study country (French, Italian, Spanish or Portuguese according to the country).
- Person under guardianship or curatorship.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Group A: standard of care
The patient will follow the hygiene-dietetic recommendations given by their centre and wear an actigraph night and day.
|
Between visits, tha patient will have to:
|
Other: Group B: standard of care + mobile application CardiCare™
The patient will follow the hygiene-dietetic recommendations given by their centre, wear an actigraph night and day and use the mobile application CardiCare™
|
Between visits, tha patient will have to:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the efficacy at 6 months of CardiCare™ in stabilising or improving the Cardiorespiratory Fitness of patients after acute coronary syndrome, graduated from a phase 2 cardiac rehabilitation program, versus standard care.
Time Frame: From day 0 to month 6
|
Proportion of participants with stabilised or improved VO2max 6 months, as measured by Cardiopulmonary Exercise Test in group B versus group A
|
From day 0 to month 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate CardiCare™ impact on global physical activity between both groups over time of follow-up.
Time Frame: From day 0 to month 6
|
The global physical activity will be monitored using continuous variables of the actigraph
|
From day 0 to month 6
|
To evaluate CardiCare™ impact on change in cardiorespiratory fitness at 3 months versus baseline in both groups.
Time Frame: From day 0 to month 3
|
Proportion of participants in group B versus group A with stabilised or improved VO2max at 3 months compared to baseline.
|
From day 0 to month 3
|
To evaluate CardiCare™ impact on change in other cardiorespiratory fitness parameters at 3 and 6 months versus baseline, in both groups
Time Frame: From day 0 to month 3 and month 6
|
Comparison in continous measurement of cardiorespiratory fitness as measured by Cardiopulmonary Exercise Test
|
From day 0 to month 3 and month 6
|
To evaluate CardiCare™ impact on change in lipid levels at 3 and 6 months versus baseline, in both groups.
Time Frame: From day 0 to month 3 and month 6
|
Identification of items will be based in continuous measurement of total cholesterol, Low Density Lipoproteins Cholesterol, High Density lipoproteins Cholesterol.
|
From day 0 to month 3 and month 6
|
To evaluate CardiCare™ impact on change in glucose levels at 3 and 6 months versus baseline, in both groups.
Time Frame: From day 0 to month 3 and month 6
|
Identification of items will be based in continuous measurement of fasting glucose
|
From day 0 to month 3 and month 6
|
To evaluate CardiCare™ impact on change in weight at 3 months and 6 months versus baseline in both groups.
Time Frame: From day 0 to month 3 and month 6
|
Identification of items will be based on measured clinical exam
|
From day 0 to month 3 and month 6
|
To evaluate CardiCare™ impact on change in Body Mass Index at 3 months and 6 months versus baseline in both groups.
Time Frame: From day 0 to month 3 and month 6
|
Identification of items will be based on measured clinical exam
|
From day 0 to month 3 and month 6
|
To evaluate CardiCare™ impact on change in Hip and waist circumference at 3 months and 6 months versus baseline in both groups.
Time Frame: From day 0 to month 3 and month 6
|
Identification of items will be based on measured clinical exam
|
From day 0 to month 3 and month 6
|
To evaluate the impact of CardiCare™ on anxiety at 3 and 6 months versus baseline, in both groups.
Time Frame: From day 0 to month 3 and month 6
|
Identification of the items will be measure with Hospital Anxiety and Depression Scale questionnaires
|
From day 0 to month 3 and month 6
|
To evaluate the impact of CardiCare™ on quality of life at 3 and 6 months versus baseline, in both groups.
Time Frame: From day 0 to month 3 and month 6
|
Identification of the items will be measure with Health-Related Quality of Life questionnaires
|
From day 0 to month 3 and month 6
|
To evaluate medication compliance in both groups.
Time Frame: From day 0 to month 6
|
Compliance will based on the duration of medication interruption.
|
From day 0 to month 6
|
To compare differences of reported cardiovascular events at 3 and 6 months, in both groups.
Time Frame: From day 0 to month 3 and month 6
|
Comparison will based on the number of cardiovascular events occured
|
From day 0 to month 3 and month 6
|
To compare time to first hospital readmission among both groups (all-cause, cardiac, and noncardiac) and their predictors.
Time Frame: From day 0 to month 3 and month 6
|
Comparison will based on the number of hospital readmission
|
From day 0 to month 3 and month 6
|
To assess the cost-effectiveness to reduce 30-day, 3 months and 6 months readmission rates using CardiCare™ as an intervention compared to standard care.
Time Frame: From day 0 to month 3 and month 6
|
Identification of the items based on the number of hospital readmission
|
From day 0 to month 3 and month 6
|
To evaluate the impact of CardiCare™ on employment status at 3 and 6 months versus baseline in both groups.
Time Frame: From day 0 to month 3 and month 6
|
Identification of the items will based on the time to return to work and the time in sick leave
|
From day 0 to month 3 and month 6
|
To evaluate CardiCare™ impact on exercise performed in group B.
Time Frame: From day 0 to month 6
|
Comparison of the exercise performed during the follow up of participants in group B.
|
From day 0 to month 6
|
To evaluate CardiCare™ impact on cardiovascular risk factors control at 3 and 6 months versus baseline in both groups.
Time Frame: From day 0 to month 3 and month 6
|
Identification of the cardiovascular risk factors will based on the clinical exam and blood tests
|
From day 0 to month 3 and month 6
|
To evaluate, for each session, the correlation between self-reported physical activities in CardiCare™ and those collected by the actigraph in group B.
Time Frame: From day 0 to month 6
|
Identification of items will be based on the physical activities reported by the patient in CardiCare™ and actigraph
|
From day 0 to month 6
|
To identify patterns of VO2max evolution between D0, M3 and M6, between both groups
Time Frame: From day 0 to month 3 and month 6
|
Identification of items will be based on the measures of cardiorespiratory fitness as measured by Cardiopulmonary Exercise Test
|
From day 0 to month 3 and month 6
|
To evaluate CardiCare™ impact on sleep quality between groups over time of follow-up.
Time Frame: From day 0 to month 6
|
Identification of the items be based on actigraph
|
From day 0 to month 6
|
To evaluate the safety of the CardiCare™ use.
Time Frame: From day 0 to month 6
|
Safety will be assessed by the numbers of adverse events and adverse events related to the use of the application CardiCare™.
|
From day 0 to month 6
|
To collect patients and investigators feedback on the CardiCare™ application.
Time Frame: From day 0 to month 6
|
Descriptive analysis of patients and investigators satisfaction related to the mobile application.
|
From day 0 to month 6
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Alain Cohen Solal, Prof, Lariboisière Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CardiCare
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Coronary Syndrome
-
Yonsei UniversityRecruitingCoronary Artery Disease, Acute Coronary SyndromeKorea, Republic of
-
Meditrix CorpNational University of Ireland, Galway, Ireland; Boston Scientific Japan K.K.; Fujita Health UniversityRecruitingChronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromeJapan, Ireland
-
OrbusNeichDuke Clinical Research Institute; OrbusNeich Medical K.K.CompletedCoronary Arteriosclerosis | Non ST Segment Elevation Acute Coronary SyndromeUnited States, Japan
-
Medical University of WarsawRecruitingAcute Coronary Syndrome | Chronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromePoland
-
Niguarda HospitalCompletedAcute Coronary Syndrome With ST Elevation on Electrocardiogram | Acute Coronary Syndrome Without ST Elevation on Electrocardiogram | Noncritical Coronary Artery Disease Coronary Stenosis Less Than 50 Per Cent | Aortic AneurysmsItaly
-
Sohag UniversityRecruitingLeft Main Coronary Artery Disease With Acute Coronary SyndromeEgypt
-
Eli Lilly and CompanyDaiichi Sankyo, Inc.CompletedCoronary Arteriosclerosis | Acute Coronary SyndromesUnited States
-
University of PatrasCompletedCoronary Artery Disease (CAD) | Acute Coronary Syndrome (ACS)Greece
-
The First Affiliated Hospital with Nanjing Medical...Unknown
-
Yonsei UniversityCompletedAcute Coronary Syndrome (ACS)Korea, Republic of
Clinical Trials on Wear an actigraph
-
The Catholic University of KoreaCompletedQuality of Life | Cerebral Palsy | Physical Activity | Sleep Disorder | Parenting | Physical DisabilityKorea, Republic of
-
Ad scientiamCompleted
-
Becton, Dickinson and CompanyCompleted
-
VA Office of Research and DevelopmentCompletedSuicidal Ideation | Suicidal Behavior | Mental Health Symptoms | Mental Health HospitalizationsUnited States
-
IRCCS Fondazione Stella MarisMinistry of Health, Italy; The University of Queensland; Scuola Superiore Sant...Completed
-
Memorial Sloan Kettering Cancer CenterJohns Hopkins University; Weill Medical College of Cornell UniversityCompleted
-
University of FloridaAlign Technology, Inc.RecruitingOrthodontic Tooth MovementUnited States
-
Newcastle UniversityRecruiting
-
M.D. Anderson Cancer CenterCompleted
-
Taipei Medical University Shuang Ho HospitalSponsor GmbHCompleted